UK Watchdog Turns Down Liraglutide (Saxenda) for Obesity UK Watchdog Turns Down Liraglutide (Saxenda) for Obesity
UK NICE cites"highly uncertain" cost-effectiveness estimates for liraglutide (Saxenda) for obesity and questions the appropriateness of a subgroup analysis of the SCALE trial in a draft ruling.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 30, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Could Liraglutide Stall the Onset of Type 2 Diabetes in Kids? Could Liraglutide Stall the Onset of Type 2 Diabetes in Kids?
Results promising for the GLP-1 agonist in the treatment of children and adolescents with type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 16, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Liraglutide Ups Risk for Gallbladder, Biliary Tract Events
MONDAY, Aug. 26, 2019 -- There is an increased risk for gallbladder- or biliary tract-related events among patients with type 2 diabetes taking liraglutide versus placebo, according to a study published online Aug. 9 in Diabetes Care. Michael A.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 26, 2019 Category: Pharmaceuticals Source Type: news

Gallbladder, Biliary Tract Events Increased With Liraglutide Gallbladder, Biliary Tract Events Increased With Liraglutide
Post-hoc analysis from the LEADER trial explores the relevant factors and potential mechanisms.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 20, 2019 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

New ADA Update: Liraglutide for Youth and Technology Issues New ADA Update: Liraglutide for Youth and Technology Issues
Liraglutide for youth, dulaglutide cardiovascular outcomes data, and'time-in-range'guidelines inform the latest Living Standards updates.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 2, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

EU approves type 2 diabetes drug for children
The Committee for Medicinal Products for Human Use of the European Medicines Agency has approved the GLP-1 agonist, liraglutide, for the treatment of children and adolescents with type 2 diabetes.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - July 4, 2019 Category: Endocrinology Source Type: news

EU OKs Liraglutide in Kids; Rejects Romosozumab for Osteoporosis EU OKs Liraglutide in Kids; Rejects Romosozumab for Osteoporosis
The CHMP recommended approval of the GLP-1 agonist liraglutide for type 2 diabetes in children aged 10 and older, but it recommended refusal of marketing authorization for osteoporosis agent romosozumab.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Victoza Injection for Children 10 Years and Older
Title: FDA Approves Victoza Injection for Children 10 Years and OlderCategory: Health NewsCreated: 6/18/2019 12:00:00 AMLast Editorial Review: 6/19/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - June 19, 2019 Category: Endocrinology Source Type: news

FDA Approves Victoza Injection for Children 10 Years and Older with Type 2 Diabetes
TUESDAY, June 18, 2019 -- Victoza (liraglutide) injection is now approved to treat type 2 diabetes in children 10 years and older, the U.S. Food and Drug Administration announced. Approved to treat type 2 diabetes in adults in 2010, Victoza is the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 18, 2019 Category: General Medicine Source Type: news

FDA Approves Victoza Injection for Children 10 Years and Older
TUESDAY, June 18, 2019 -- Victoza (liraglutide) injection is now approved to treat type 2 diabetes in children 10 years and older, the U.S. Food and Drug Administration announced yesterday. Approved to treat type 2 diabetes in adults in 2010,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 18, 2019 Category: Pharmaceuticals Source Type: news

FDA OKs Liraglutide for Use in Youth With Type 2 Diabetes FDA OKs Liraglutide for Use in Youth With Type 2 Diabetes
Liraglutide is the first noninsulin agent approved to treat pediatric type 2 diabetes in nearly 20 years; approval comes at a time when doctors are increasingly concerned about type 2 diabetes in kids.FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - June 18, 2019 Category: Pediatrics Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Victoza (liraglutide) for the Treatment of Pediatric Patients 10 Years or Older with Type 2 Diabetes
June 17, 2019 -- The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 17, 2019 Category: Drugs & Pharmacology Source Type: news

ADA: Combo Injectable Controls Blood Glucose Longer in T2DM
FRIDAY, June 14, 2019 -- Compared with insulin glargine, initial injectable therapy with a combination of insulin degludec and liraglutide aids achievement of blood glucose goals for a longer period of time in patients with uncontrolled type 2... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2019 Category: Pharmaceuticals Source Type: news

Xultophy (insulin degludec and liraglutide injection)
Title: Xultophy (insulin degludec and liraglutide injection)Category: MedicationsCreated: 6/12/2019 12:00:00 AMLast Editorial Review: 6/12/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 12, 2019 Category: Drugs & Pharmacology Source Type: news

Little Difference With Oral Semaglutide vs Liraglutide in Diabetes Little Difference With Oral Semaglutide vs Liraglutide in Diabetes
PIONEER 4 trial shows noninferiority of oral semaglutide to liraglutide for HbA1c lowering, while PIONEER 7 shows superior glycemic control and weight loss compared with the DPP-4 inhibitor sitagliptin.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 12, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Liraglutide Preserves Beta-Cell Function in New Type 1 Diabetes Liraglutide Preserves Beta-Cell Function in New Type 1 Diabetes
Patients with newly diagnosed type 1 diabetes put on liraglutide, in addition to insulin, show greater preservation of insulin production 1 year after diagnosis in an intriguing, although small, study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 10, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Combination medication helps patients with type 2 diabetes maintain blood sugar goals
(Brigham and Women's Hospital) Through a randomized, multicenter clinical trial, investigators studied blood glucose results for patients assigned to either take insulin (insulin glargine, IGlar U100) or insulin degludec plus liraglutide (IDegLira), a combination of both insulin and an additional medication to help with blood sugar control. The global study team found that participants who received IDegLira were better able to achieve blood glucose goals and remain at that goal longer compared to those assigned to receive IGlar. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 9, 2019 Category: International Medicine & Public Health Source Type: news

Newer Diabetes Drug, Liraglutide (Victoza), Shows Promise in Kids, Teens
TUESDAY, April 30, 2019 -- A type 2 diabetes drug for adults also controls blood sugar levels in children and teens with the disease, researchers report. Type 2 diabetes is on the rise among children and teens, but they have fewer treatment choices... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 30, 2019 Category: General Medicine Source Type: news

Newer Diabetes Drug Liraglutide Shows Promise in Kids, Teens
TUESDAY, April 30, 2019 -- A type 2 diabetes drug for adults also controls blood sugar levels in children and teens with the disease, researchers report. Type 2 diabetes is on the rise among children and teens, but they have fewer treatment choices... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 30, 2019 Category: General Medicine Source Type: news

Liraglutide Added to Metformin Effective for Type 2 Diabetes
MONDAY, April 29, 2019 -- The addition of liraglutide to metformin is effective and safe for children and adolescents with type 2 diabetes, according to a study published online April 28 in the New England Journal of Medicine to coincide with the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 29, 2019 Category: Pharmaceuticals Source Type: news

Drug treats Type 2 diabetes in children, team announces
(University of Texas Health Science Center at San Antonio) Jane Lynch, M.D., FAAP, professor of pediatrics at UT Health San Antonio, said the drug liraglutide, in combination with an existing medication, metformin, showed robust effect in treating children with type 2 diabetes who were studied in the Ellipse trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 29, 2019 Category: International Medicine & Public Health Source Type: news

ELLIPSE: Liraglutide Effective for Diabetes in Adolescents ELLIPSE: Liraglutide Effective for Diabetes in Adolescents
This is a'practice-changing'study, says the lead author, since'metformin fails quickly as monotherapy in type 2 diabetes kids and insulin is the only second-line drug approved'for these children.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 29, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Finally, another effective drug for kids and teens with type 2 diabetes
A new drug, liraglutide, will be “transformational” for youth with type 2 diabetes, according to new Yale-led research in the New England Journal of Medicine. (Source: Yale Science and Health News)
Source: Yale Science and Health News - April 28, 2019 Category: Universities & Medical Training Source Type: news

Efficacy and Safety of IDegLira in Older Patients With T2D Efficacy and Safety of IDegLira in Older Patients With T2D
IDegLira is an insulin degludec/liraglutide combination that has been shown to improve glycemic control in type 2 diabetes. Is it a safe and effective option for older patients?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Metformin vs. Victoza
Title: Metformin vs. VictozaCategory: MedicationsCreated: 12/19/2018 12:00:00 AMLast Editorial Review: 12/19/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 19, 2018 Category: Drugs & Pharmacology Source Type: news

Diabetes drug liraglutide linked to lower risk of cardiovascular events
(Karolinska Institutet) Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Sweden, is published in The Lancet Diabetes& Endocrinology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2018 Category: International Medicine & Public Health Source Type: news

IBT Plus Liraglutide Boosts Weight Loss in Obese Patients
(MedPage Today) -- Adding pharmacotherapy also led to beneficial changes in appetite (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 15, 2018 Category: Endocrinology Source Type: news

Study: Diabetes drug also may reduce heart disease risk
Diabetes patients who take liraglutide to treat their sugar levels might also reduce risk for heart disease, according to a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 27, 2018 Category: Consumer Health News Source Type: news

A New Player in Type 1 Diabetes Treatment?
Liraglutide: A New Player in Type 1 Diabetes Treatment? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 10, 2018 Category: General Medicine Source Type: news

Liraglutide: A New Player in Type 1 Diabetes Treatment? Liraglutide: A New Player in Type 1 Diabetes Treatment?
In a randomized, placebo-controlled trial, liraglutide added to insulin improved glycemic control and reduced weight and blood pressure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Novo's pioneering diabetes pill beats Victoza, Januvia in tests
COPENHAGEN (Reuters) - Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck& Co's Januvia and its own best-selling injectable treatment Victoza in tests. (Source: Reuters: Health)
Source: Reuters: Health - June 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Study offers new hope for the fight against genetically determined obesity
(University of Copenhagen The Faculty of Health and Medical Sciences) A large group of people with obesity have a genetic mutation that is causing their obesity. Common treatments for obesity only benefit these people to a limited extent, but now a new study conducted at the University of Copenhagen reveals that they can be treated effectively with the medicine liraglutide, which is a GLP-1 receptor agonist. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news

Liraglutide cost saving versus sitagliptin for T2DM
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

Xultophy Injection (Insulin Degludec and Liraglutide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 21, 2017 Category: Drugs & Pharmacology Source Type: news

Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for Victoza
Novo Nordisk (NYSE:NVO) said today that it inked a value-based contract for its Type II diabetes drug, Victoza, with pharmacy benefit manager Prime Therapeutics. The agreement is part of Prime’s CareCentered Contract program. Under the terms of the deal, Prime will evaluate Victoza’s efficacy and will reimburse commercial clients if certain measures aren’t met, according to the company. Get the full story at our sister site, Drug Delivery Business News. The post Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for Victoza appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news

Targeting a microRNA shows potential to enhance effectiveness of diabetes drugs
(University of Alabama at Birmingham) Researchers have found a vital role for miR-204 in beta cells -- regulating the cell surface receptor that is the target of many of the newer type 2 diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta. This drug target is the glucagon-like peptide 1 receptor, or GLP1R. Activation of GLP1R with these drugs helps the beta cell produce and secrete more insulin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news

Liraglutide linked to reduction in VAT and improvement in beta-index
For obese individuals with prediabetes or early type 2 diabetes, liraglutide is associated with a greater reduction in visceral adipose tissue (VAT) and greater improvement inβ-index, according to a study inDiabetes Care.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 27, 2017 Category: Endocrinology Source Type: news

Mayo study shows drug slows stomach emptying, may individualize obesity treatment
(Mayo Clinic) Liraglutide injection, a prescription medication used to treat type 2 diabetes and obesity is associated with marked slowing of stomach emptying and is an effective weight loss therapy. These are the findings of a randomized, double-blind, placebo-controlled study by Mayo Clinic researchers published today in The Lancet Gastroenterology& Hepatology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2017 Category: International Medicine & Public Health Source Type: news

Mayo study shows drug slows stomach emptying, may individualize obesity treatment
ROCHESTER, Minn. ??Liraglutide injection, a prescription medication used to treat type-2 diabetes and obesity is associated with marked slowing of stomach emptying and is an effective weight loss therapy. These are the findings of a randomized, double-blind, placebo-controlled study by Mayo Clinic researchers published today in The Lancet Gastroenterology& Hepatology. ?Our paper shows that [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - September 25, 2017 Category: Hospital Management Source Type: news

Novo Nordisk Settles U.S. Probe Over Diabetes Drug for Nearly $58.7 Mln Novo Nordisk Settles U.S. Probe Over Diabetes Drug for Nearly $58.7 Mln
Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker's sales staff downplayed the importance of U.S. Food and Drug Administration-mandated warnings about the cancer risks of its diabetes medication Victoza (liraglutide).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 6, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Nordisk settles DOJ ’ s Victoza marketing suit for $59m
Novo Nordisk (NYSE:NVO)  said yesterday afternoon that it inked a $58.7 million deal with the U.S. Dept. of Justice to settle an investigation into the company’s marketing practices for Victoza – its Type II diabetes drug. The agreement settles eight different lawsuits alleging that the drugmaker misled doctors by dressing salespeople as medical educators, paying physicians to prescribe its liraglutide drug and downplaying the medicine’s side effects. Get the full story at our sister site, Drug Delivery Business News. The post Nordisk settles DOJ’s Victoza marketing suit for $59m appeared ...
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news

Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 million
(Reuters) - Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker's sales staff downplayed the importance of a warning about cancer risks on the label of its diabetes medication Victoza, the U.S. Justice Department said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - September 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Liraglutide Reduces Renal Risks in Type 2 Diabetes (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM Liraglutide — a glucagon-like peptide 1 (GLP-1) agonist — lowers risks for kidney disease in patients with type 2 diabetes, according to a secondary analysis from an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 31, 2017 Category: Primary Care Source Type: news

Victoza ® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placebo.(1) This post-hoc analysis was presented today at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain. (Source: World Pharma News)
Source: World Pharma News - August 28, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Liraglutide Indicated to Reduce Risk for Cardiovascular Events (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH The type 2 diabetes drug liraglutide (Victoza) has received a new indication, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 28, 2017 Category: Primary Care Source Type: news

D.C. Week: Trump Pressures Congress on ACA Repeal
(MedPage Today) -- Also, FDA okays new indication for diabetes drug liraglutide (Victoza) (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 26, 2017 Category: American Health Source Type: news

Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 25, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Grants Liraglutide Cardiovascular Events Indication FDA Grants Liraglutide Cardiovascular Events Indication
Liraglutide becomes the second glucose-lowering drug, after empagliflozin, to receive an additional indication for cardiovascular risk reduction.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Another Diabetes Drug Scores Heart Indication
(MedPage Today) -- Liraglutide follows empagliflozin into cardiovascular approval (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2017 Category: Urology & Nephrology Source Type: news

FDA clears Nordisk ’s Victoza as only Type II diabetes drug to cut cardio risks
The FDA approved a new indication for Novo Nordisk‘s (NYSE:NVO) Victoza liraglutide injection, clearing it as the only Type II diabetes medication indicated to reduce the risk of cardiovascular diseases, like heart attack and stroke. The regulatory watchdog’s decision is based on results from Nordisk’s 9,300-patient Leader trial, which showed that Victoza significantly reduced the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut...
Source: Mass Device - August 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news